



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Antonio J. Grillo-Lopez

Group Art Unit: 1642

Application No. 09/840,872

Examiner: G. Nickol

Filed: April 25, 2001

Title: INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF CENTRAL NERVOUS
SYSTEM LYMPHOMAS

RECEIVED
AUG 05 2002
TECH CENTER 1600/2900
#6
JMY
8/7/02

* * * * *

ELECTION REPLY

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action [Restriction Requirement] mailed on July 2, 2002,
Applicants elect with traverse, Group 1, claims 1, 3-4, 5, directed to a method of treating
CNS using a non-radiolabeled anti-CD20 antibody or fragment wherein;


- (i) the CNS is leptomeningeal metastasis (LM); and
- (ii) the chemotherapeutic is methotrexate.

Applicants further note that claims 7, 9, 11, 12, 13, 14, 15, 18, 29, 30, 31, 32, 36, 37,
38, 43, 44, and 45 are readable on the elected group.

Also, while not required in the Election, Applicants further note that the preferred
route of administration is intrathecal.

Applicants traverse the requirement on the basis that this is the first known use of an antibody directed to a B cell antigen to treat a CNS lymphoma and therefore that the claims should be examined in their full scope. In any event, upon a determination that the elected species are allowable, the Examiner is respectfully requested to extend the search to other B cell antigens and chemotherapeutics.

Respectfully submitted,
Pillsbury Winthrop LLP

By: 
Robin L. Teskin
Registration No. 35,030

1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2200
(703) 905-2500 Facsimile

Date: August 2, 2002
Attorney Reference: 037003-0280609

Inventor(s): Antonio J. Grillo-Lopez

Appl. No.: 09 840,872

Series Code ↑

Serial No. ↑

Filed: April 25, 2001

Hon. Commissioner of Patents
Washington, D.C. 20231

Group Art Unit 1642

Examiner: G. Nickol

Atty. Dkt. P

0280609

2000-30-154A

M#

Client Ref

Appln. Title: Intrathecal Administration of Rituximab
for Treatment of Central Nervous
System Lymphomas

Sir:

REPLY/AMENDMENT/LETTER

AUG 05 2002

Date: August 2, 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☒ NOT made
B. ☐ Withdrawn
C. ☐ made herewith
D. ☐ made previously

For B & C
See **Required**
Separate Paper
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	**minus 0	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	***minus 0	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)	add		+ \$280/\$140 =	+ \$0	104/204
5. Original due Date: August 2, 2002	<input type="checkbox"/> NONE				
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached	(1 mo) (2 mos) (3 mos) (4 mos) (5 mos)	\$110/\$55 = \$400/\$200 = \$920/\$460 = \$1,440/\$720 = \$1,960/\$980 =	+ \$0		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract		- \$0			
8.		Extension Fee	+ \$0		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee		+ \$110/\$55	+ \$0		148/248
10. If IDS attached requires Official Fee under Rule 97 (c),	add	+ \$180	+ \$0		126
or if Rule 97(d) Request	add	+ \$180			126
11. After-Final Request Fee per rules 129(a) and 17(r)		+ \$740/370	+ \$0		146/246
12. No. of additional inventions for examination per Rule 129(b)		x \$740/370 ea	+ \$0		149/249
13. Request for Continued Examination (RCE)		+ \$740/370	+ \$0		1179/1279
14. Petition fee for			+ \$0		

15.

TOTAL FEE = \$0

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

PLEASE CHARGE
OUR DEP. ACCT

Our Deposit Account No. 03-3975)

(Our Order No. 037003 0280609

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Robin L. Teskin

Reg. No. 35,030

P.O. Box 10500
McLean, VA 22102
Tel: (703) 905-2000

Sig:

Fax: (703) 905-2500
Tel: (703) 905-2200

Atty/Sec: RLT/af

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments